Venue | Press Room | Subscribe | Site Map
TechConnect Summit 2006
Home | About the Summit | Program | Advisory Boards | About TechConnect

Producing Sponsor


Platinum Sponsor

Welsh & Katz, Ltd.

Gold Sponsor

ISTC International Science & Technology Center

Ventures Enabling Sponsor

Atomic Venture Partners

Press Sponsor

Business Wire

Partnering Sponsor


Supporting Organizations

Boston University
Midwest Research University Network

Media Sponsors

(joint with Nanotech 2006) Nature
R&D Magazine

Summit News

Event Contact

Jennifer Rocha
955 Massachusetts Ave. #313
Cambridge, MA 02139
Phone: (774) 249-8514

Copper-Dependent Non-Traditional Pro-Inflammatory Cytokine Export and Methods

Organization:Maine Medical Center Research Institute, Maine Medical Center Research Institute, US
I.P. Brief:The inventors have discovered that non-traditional export of certain pro-inflammatory cytokines lacking a signal sequence from a cell can be inhibited by copper chelation.
Summary of I.P.:Copper chelation inhibits neointima formation, macrophage infiltration and associated inflammation, cell proliferation, secretion of extracellular matrix, intimal thickening, adventitial angiogenesis, restenosis, and vascular vessel injury in general. This invention describes a unique way of managing Interleukin-1 and FGF activity at the cellular level, which leads to the opportunity for a variety of therapeutic benefit. In vivo data has been generated and is available under a confidentiality agreement. Advantages: This invention provides novel methods for preventing and treating various diseases, including Alzheimers, Lupus, and Arthritis. There is a striking similarity to the structure of FGF and therefore leads to the hypothesis that these may be treated like a vascular disease. There are complimentary patents available as well.
Patent:Patents pending
Keywords:FGF, IL-1, lupus, alzheimers, arthritis
Primary Industry:Pharma & Biotech
Specific Market:Alzheimers, Lupus, Arthritis
Market Size:In excess of $1 billion
State of the Art:There are various strategies for each indication.
Figures of Merit:This is part of a broad family of IP that can be used to address these indications.
Tech.  Obstacles:None known at this time.
Market Obstacles:Need to move from mouse models to larger animal models to validate the concept.
Publications:Tarantini, F., Micucci, I., Bellum, S., Landriscina, M., Garfinkel, S., Prudovsky, I., and T. Maciag. The Precursor But Not the Mature Form of IL1• Blocks the Release of FGF1 in Response to Heat Shock, J. Biol. Chem., Rapid Commun., 2001; 276:5147-5151. Prudovsky, I., Mandinova, A., Soldi, R., Bagalá, C., Graziani, I., Landriscina, M., Tarantini, F., Duarte, M., Bellum, S., Doherty, H. and Maciag, T. The Non-Classical Export Routes: IL1 and FGF1 Point the Way. J. Cell Sci. 2003; 118:4871-81.
Research Team:Igor Prudovsky


Home | About the Summit | Program | Advisory Boards | About TechConnect
Terms of use | Privacy policy | Contact | TechConnect Home
© 2005 TechConnect. All rights reserved.